title: Sequential therapy of transarterial chemoembolisation and sorafenib in intermediate stage hepatocellular carcinoma.
abstract: BACKGROUND
  Prolongation of median survival can be achieved for intermediate Barcelona Clinic Liver Cancer stage hepatocellular carcinoma (HCC) by transarterial chemoembolisation (TACE). TACE might induce induction of angiogenic factors, especially in patients not responding to TACE, which might result in further tumour progression with development of new satellite lesions.
  
  
  METHODS
  Here, we report a patient with intermediate stage HCC, who initially responded to TACE, but developed new satellite lesions. After careful discussion, TACE was stopped, and a sequential treatment with sorafenib, a vascular endothelial growth factor receptor and RAF tyrosinkinase inhibitor, was started, resulting in a progression-free survival of 10 months.
  
  
  CONCLUSIONS
  The presented case demonstrates the feasibility of sequential TACE and sorafenib treatment. Results of ongoing controlled, clinical trials in this regard are awaited.
authors.forename: Martin-Walter
authors.initials: MW
authors.lastname: Welker
authors.forename: Stephan
authors.initials: S
authors.lastname: Zangos
authors.forename: Susanne
authors.initials: S
authors.lastname: Kriener
authors.forename: Christian
authors.initials: C
authors.lastname: Mönch
authors.forename: Stefan
authors.initials: S
authors.lastname: Zeuzem
authors.forename: Joerg
authors.initials: J
authors.lastname: Trojan
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001557:Benzenesulfonates / Q000008:administration & dosage*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D016461:Chemoembolization, Therapeutic / Q000379:methods*; D018572:Disease-Free Survival; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000008:administration & dosage*; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib
references.citation: Cancer. 2001 Jun 15;91(12):2386-93
references.pmid: 11413529
references.citation: World J Gastroenterol. 2004 Oct 1;10(19):2878-82
references.pmid: 15334691
references.citation: Hepatology. 2003 Feb;37(2):429-42
references.pmid: 12540794
references.citation: J Natl Cancer Inst. 2008 May 21;100(10):698-711
references.pmid: 18477802
references.citation: Expert Rev Anticancer Ther. 2008 Nov;8(11):1743-9
references.pmid: 18983234
references.citation: BMC Cancer. 2008 Nov 26;8:349
references.pmid: 19036146
references.citation: Am J Gastroenterol. 2008 Apr;103(4):914-21
references.pmid: 18177453
references.citation: Eur J Radiol. 2009 Dec;72(3):505-16
references.pmid: 18835117
references.citation: N Engl J Med. 2008 Jul 24;359(4):378-90
references.pmid: 18650514
references.citation: Oncology. 2008;75 Suppl 1:1-12
references.pmid: 19092266
references.citation: Semin Liver Dis. 1999;19(3):329-38
references.pmid: 10518312
references.citation: Eur J Gastroenterol Hepatol. 2001 Mar;13(3):291-4
references.pmid: 11293452
references.citation: Lancet. 2003 Dec 6;362(9399):1907-17
references.pmid: 14667750
references.citation: Crit Rev Oncol Hematol. 2008 Jul;67(1):8-15
references.pmid: 18434184